Galecto (GLTO) Q4 2025 earnings summary

Executive summary

• Completed acquisition of a pipeline targeting mutant calreticulin-driven MPNs, including lead candidate DMR-001, and secured $285 million in private financing.

• Strengthened leadership with new COO and CMO appointments, enhancing hematology/oncology expertise.

• Changed company name and began trading under new ticker symbol on Nasdaq in March 2026.

Financial highlights

• Cash and cash equivalents were $257.6 million as of December 31, 2025, rising to $535 million by February 28, 2026, after a public offering.

• Research and development expenses increased to $26.9 million in 2025 from $6.4 million in 2024, driven by acquisition and expanded activities.

• General and administrative expenses decreased to $9.7 million in 2025 from $10.5 million in 2024, mainly due to lower stock-based compensation.

• Net loss for 2025 was $209.8 million, up from $21.4 million in 2024, primarily due to $174.3 million in acquired in-process R&D costs.

Outlook and guidance

• IND or CTA submission for DMR-001 expected mid-2026; DMR-002 in the second half of 2026; DMR-003 in 2027.

• Two clinical proof-of-concept datasets for DMR-001 anticipated beginning mid-2027.

• Cash position expected to fund operations into Phase 3 development of DMR-001.